A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
← catalyst calendarNCT06130553 · readout in 837 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
334estimated
Sites
21
Countries
Australia, China, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-18 | actual | When the study began enrolling |
| Primary completion | 2028-12-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-04 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors That Are MTAP Deficient
Interventions
- Drug: AZD3470
- Drug: Datopotamab deruxtecan — also filed as Dato-DXd
Primary outcomes
what the primary-completion date above is the date OFAll Modules: Incidence of adverse events (AEs) and serious adverse events (SAEs). To determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agents
measured From time of informed consent to 28 days post last dose of study treatment
Module 1: Incidence of dose-limiting toxicities (DLT)
measured From first dose of study treatment until the end of Cycle 1 (each cycle is 21 days)
Module 2: Progression Free Survival assessed by the Investigator according to RECIST v1.1
measured From date of randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed